Key result
Elevated serum IL-1β predicts ~126% greater no-reflow risk per SD during primary PCI for STEMI.
Why the study?
Over 10% of STEMI patients develop no-reflow after PPCI, driven by microvascular inflammation linked to pyroptosis and ferroptosis, but the biomarker potential of these pathways remains unclear.
Does elevated pre-PCI serum IL-1β predict the no-reflow phenomenon in STEMI patients undergoing primary PCI?
Does elevated pre-PCI serum IL-1β predict the no-reflow phenomenon in STEMI patients undergoing primary PCI?
Elevated pre-PCI serum IL-1β independently predicts the no-reflow phenomenon in STEMI patients, offering a novel biomarker to enhance risk stratification.
Answers are grounded in this paper and cite their sources.
May improve no-reflow risk stratification in STEMI; hypothesis-generating and requires prospective validation before clinical adoption.
Purpose: Despite primary percutaneous coronary intervention (PPCI), over 10% of ST-segment elevation myocardial infarction (STEMI) patients develop the no-reflow phenomenon, characterized by microvascular inflammation. Novel forms of cell death, such as pyroptosis (IL-1β/GSDMD/Caspase-1) and ferroptosis (ACSL4/GPX4/PTGS2), may contribute to this inflammation by promoting cytokine release and leukocyte recruitment. However, the biomarker potential of these pathways in predicting no-reflow remains unclear. This study aimed to evaluate whether serum levels of these proteins could predict no-reflow and improve risk stratification. Patients and Methods: We enrolled 423 STEMI patients undergoing PPCI at two centers. No-reflow was defined as TIMI flow <3 following PPCI, excluding mechanical obstruction. Serum levels of pyroptosis- (IL-1β, GSDMD, Caspase-1) and ferroptosis-related proteins (ACSL4, GPX4, PTGS2) were measured using ELISA. Multivariable logistic regression identified independent predictors. The baseline model included age, sex, cardiovascular risk factors, and other baseline differences. Biomarker performance was assessed using ROC analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: Of 423 patients, 81 (19.1%) developed no-reflow. The no-reflow group had significantly higher IL-1β [7.41 (5.55-10.80) vs 4.91 (3.70-6.71) pg/mL, P<0.001] and GSDMD levels [2.34 (1.75-3.48) vs 2.05 (1.64-2.71) ng/mL, P=0.017]. IL-1β was an independent predictor of no-reflow in both continuous [per SD increase: adjusted OR=2.260, 95% CI 1.723-2.966, P<0.001] and categorical analyses [highest vs lowest tertile: OR=6.484, 95% CI 2.864-14.679, P<0.001]. ROC analysis showed IL-1β alone had an AUC of 0.745 (95% CI: 0.686-0.804) for no-reflow prediction. Adding IL-1β to the baseline model improved discrimination (ΔAUC=0.091, P<0.001; NRI=0.627, P<0.001; IDI=0.109, P<0.001). Conclusion: Elevated serum IL-1β independently predicts no-reflow in STEMI patients, and its integration into the baseline model significantly enhances diagnostic performance, suggesting IL-1β as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question. Elevated serum IL-1β independently predicted no-reflow in STEMI patients undergoing primary PCI and improved risk discrimination.
Synapse has enriched 10 related papers. Consider them for comparative context: